Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Role of Nutritional Intervention With Friliver for the Treatment of Sarcopenia in Cirrhotic Patients With Refractory Ascites Candidate to Transjugular Intrahepatic Portosystemic Shunt Placement and Identification of Prognostic Factors Related to Clinical Outcome
Authors not listed
The Mediterranean Institute for Transplantation and Advanced Specialized Therapies · 2022
Abstract
The hypothesis is that in patients with cirrhosis and refractory ascites candidate to TIPS, and sarcopenia (identified by a PMA ≤16 cm² at the level of L3), who are at high-risk of 6-month mortality after TIPS placement, a post-TIPS 12 weeks nutritional intervention is associated with improved post-TIPS prognosis.
The primary objective is to evaluate the effect of a post-TIPS 12 weeks nutritional intervention on liver transplant-free six-month survival in sarcopenic candidates to TIPS for refractory ascites in cirrhosis.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-22 MST
Cite this
APA
Anonymous. (2022). Role of Nutritional Intervention With Friliver for the Treatment of Sarcopenia in Cirrhotic Patients With Refractory Ascites Candidate to Transjugular Intrahepatic Portosystemic Shunt Placement and Identification of Prognostic Factors Related to Clinical Outcome. <em>The Mediterranean Institute for Transplantation and Advanced Specialized Therapies</em>. https://clinicaltrials.gov/study/NCT06814626
Vancouver
Anonymous. Role of Nutritional Intervention With Friliver for the Treatment of Sarcopenia in Cirrhotic Patients With Refractory Ascites Candidate to Transjugular Intrahepatic Portosystemic Shunt Placement and Identification of Prognostic Factors Related to Clinical Outcome. The Mediterranean Institute for Transplantation and Advanced Specialized Therapies. 2022.
BibTeX
@misc{anon2022Roleof,
title = {Role of Nutritional Intervention With Friliver for the Treatment of Sarcopenia in Cirrhotic Patients With Refractory Ascites Candidate to Transjugular Intrahepatic Portosystemic Shunt Placement and Identification of Prognostic Factors Related to Clinical Outcome},
author = {Anonymous},
journal = {The Mediterranean Institute for Transplantation and Advanced Specialized Therapies},
year = {2022},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Anna Baiges 2022
Open access · US-GOV
Expanding the Therapeutic Landscape of Post-TIPS Hepatic Encephalopathy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 2025
Open access · US-GOV
Mechanism of Transjugular Intrahepatic Portosystemic Shunt to Improve Sarcopenia by Down-regulation of FGF21
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization 2021
Open access · US-GOV
Comparison of the Swallowing Functions of the Sarcopenia and Dynapenia Patients
Puerta de Hierro University Hospital 2017
Open access · US-GOV
Characterization of the Nutritional Status in the Patient With Liver Cirrhosis and Impact of a Nutritional Intervention With Nutritional Supplements With BRCA vs. Standard Treatment in the Subgroup of Patients With Sarcopenia
Hospital Clinic of Barcelona 2021
Open access · US-GOV
Comparison of Two Nutritional Screening Tools for the Detection of Malnutrition in Patients with Liver Cirrhosis
Xiaosun Liu, MD 2024
Open access · US-GOV